MMSI Merit Medical Systems Inc

Merit Medical Systems, Inc. (NASDAQ:MMSI) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $105.88. The company recently reported strong quarterly earnings and revenue, surpassing analyst estimates, and has set optimistic full-year 2025 guidance. Despite recent insider selling, institutional investors hold a significant portion of the stock.

Assenagon Asset Management S.A. has acquired 19,750 shares of Merit Medical Systems, Inc. in the third quarter, valued at approximately $1.64 million, with institutional investors now holding 99.66% of the stock. Insider selling, specifically by Chairman Fred P. Lampropoulos, has amounted to 60,000 shares in the last 90 days. Merit Medical Systems surpassed Q3 earnings expectations, reporting a revenue increase of 13% year-over-year and forecasting FY2025 EPS between $3.66 and $3.79, while analysts maintain a "Moderate Buy" rating with an average price target of $105.88.

Merit Medical Systems, Inc. (MMSI) is well-positioned for future growth due to its strong product portfolio, sustained organic growth in its cardiovascular segment, and significant margin expansion, as evidenced by its third-quarter performance. While challenges like tariff uncertainties and integration risks from acquisitions exist, the company's WRAPSODY CIE commercial traction and positive estimate revisions for 2025 earnings per share indicate a favorable outlook. The stock is currently a Zacks Rank #3 (Hold) but shows potential for long-term investors.

Squarepoint Ops LLC drastically reduced its stake in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 94.7% in Q2, selling 203,594 shares and retaining 11,495 shares valued at $1.08 million. This comes as company insiders also sold 60,000 shares worth approximately $5.19 million, though insiders collectively still own 3.70% of the stock. Despite this, Merit Medical Systems demonstrated strong Q3 earnings, beating analyst estimates, and has an average analyst rating of "Moderate Buy" with a target price of $105.88.

This article analyzes Merit Medical Systems Inc. (NASDAQ: MMSI) stock, highlighting its price action as crucial for tactical trading. It notes a potential shift in positive near-term sentiment amidst broader weak alignment and resistance testing. The analysis provides specific institutional trading strategies, including long, breakout, and short setups with defined entry, target, and stop-loss zones, based on AI-generated signals and multi-timeframe analysis.

Congress Asset Management Co. significantly increased its stake in Merit Medical Systems, Inc. to 672,901 shares, valuing its position at $56.01 million. This comes as Chairman Fred P. Lampropoulos sold a portion of his shares, while the company reported strong Q3 earnings, beating analyst expectations with $0.92 EPS and a 13% revenue growth, and analysts maintain a "Moderate Buy" rating with a consensus price target of $105.88.